View source for Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI)

__NOTOC__
{{Percutaneous Coronary Intervention}}
{{CMG}}

==2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83 |year=2011 |month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>==
===Intravenous Antiplatelet Therapy in Unstable Angina/Non-ST Elevation Myocardial Infarction (UA/NSTEMI) (DO NOT EDIT)<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83 |year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>===


{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]

|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' In [[Unstable angina / non ST elevation myocardial infarction|UA/NSTEMI]] patients with high-risk features (e.g., [[Unstable angina / non ST elevation myocardial infarction biomarkers#Cardiac Troponins|elevated troponin level]]) not treated with [[Unstable angina / non ST elevation myocardial infarction direct thrombin inhibitors therapy|bivalirudin]] and not adequately pre-treated with [[Unstable angina / non ST elevation myocardial infarction thienopyridines|clopidogrel]], it is useful at the time of [[Unstable angina / non ST elevation myocardial infarction recommendations for PCI|PCI]] to administer a [[Unstable angina / non ST elevation myocardial infarction GPIIb/IIIa inhibitor|GP IIb/IIIa inhibitor]] ([[abciximab]],[[eptifibatide|double-bolus eptifibatide]], or [[tirofiban|high-bolus dose tirofiban]]) in patients treated with [[Unstable angina / non ST elevation myocardial infarction unfractionated heparin therapy|unfractionated heparin therapy (UFH)]].<ref name="pmid9182212">{{cite journal |author= |title=Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators |journal=[[The New England Journal of Medicine]] |volume=336 |issue=24 |pages=1689–96|year=1997 |month=June |pmid=9182212 |doi=10.1056/NEJM199706123362401|url=http://dx.doi.org/10.1056/NEJM199706123362401 |accessdate=2011-12-15}}</ref><ref name="pmid10562258">{{cite journal |author=Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML |title=Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention |journal=[[Circulation]] |volume=100 |issue=20 |pages=2045–8|year=1999 |month=November |pmid=10562258 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=10562258 |accessdate=2011-12-15}}</ref><ref name="pmid10341274">{{cite journal|author=Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML |title=Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators |journal=[[The New England Journal of Medicine]] |volume=340 |issue=21|pages=1623–9 |year=1999 |month=May |pmid=10341274 |doi=10.1056/NEJM199905273402103|url=http://dx.doi.org/10.1056/NEJM199905273402103 |accessdate=2011-12-15}}</ref><ref name="pmid16981067">{{cite journal |author=Sosnowski C |title=[Commentary to the article: Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-8] |language=Polish |journal=[[Kardiologia Polska]] |volume=64 |issue=8|pages=913–6; discussion 917–8 |year=2006 |month=August |pmid=16981067 |doi=|url=http://www.kardiologiapolska.pl/en/darmowy_pdf.phtml?id=43&indeks_art=946|accessdate=2011-12-15}}</ref><ref name="pmid11733392">{{cite journal |author=Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ |title=Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes |journal=[[Circulation]] |volume=104|issue=23 |pages=2767–71 |year=2001 |month=December |pmid=11733392 |doi=|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11733392|accessdate=2011-12-15}}</ref><ref name="pmid8121459">{{cite journal |author= |title=Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation |journal=[[The New England Journal of Medicine]]|volume=330 |issue=14 |pages=956–61 |year=1994 |month=April |pmid=8121459|doi=10.1056/NEJM199404073301402 |url=http://dx.doi.org/10.1056/NEJM199404073301402|accessdate=2011-12-15}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|}

{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]

|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In [[Unstable angina / non ST elevation myocardial infarction|UA/NSTEMI]] patients with high-risk features (e.g., [[Unstable angina / non ST elevation myocardial infarction biomarkers#Cardiac Troponins|elevated troponin level]]) treated with [[Unstable angina / non ST elevation myocardial infarction unfractionated heparin therapy|unfractionated heparin therapy (UFH)]] and adequately pretreated with [[Unstable angina / non ST elevation myocardial infarction thienopyridines|clopidogrel]], it is reasonable at the time of [[Unstable angina / non ST elevation myocardial infarction recommendations for PCI|PCI]] to administer a [[Unstable angina / non ST elevation myocardial infarction GPIIb/IIIa inhibitor|GP IIb/IIIa inhibitor]] ([[abciximab]],[[eptifibatide|double-bolus eptifibatide]], or [[tirofiban|high-bolus dose tirofiban]]).<ref name="pmid16981067">{{cite journal |author=Sosnowski C |title=[Commentary to the article: Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-8] |language=Polish |journal=[[Kardiologia Polska]] |volume=64 |issue=8|pages=913–6; discussion 917–8 |year=2006 |month=August |pmid=16981067 |doi=|url=http://www.kardiologiapolska.pl/en/darmowy_pdf.phtml?id=43&indeks_art=946|accessdate=2011-12-15}}</ref><ref name="pmid15234398">{{cite journal |author=Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R |title=The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial |journal=[[Journal of the American College of Cardiology]] |volume=44 |issue=1 |pages=14–9 |year=2004 |month=July |pmid=15234398|doi=10.1016/j.jacc.2004.03.042 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735109704007090|accessdate=2011-12-15}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Disease]]
[[Category:Cardiology]]

[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]